Electrochemotherapy for cutaneous and subcutaneous tumor lesions: A novel therapeutic approach

Dermatologic Therapy

Volumn 23, Issue 6, 2010, Pages 651-661

  Testori, Alessandro ^a   Tosti, Giulio ^a   Martinoli, Chiara ^a   Spadola, Giuseppe ^a   Cataldo, Francesco ^a   Verrecchia, Francesco ^a   Baldini, Federica ^a   Mosconi, Massimo ^a   Soteldo, Javier ^a   Tedeschi, Ines ^a   Passoni, Claudia ^a   Pari, Chiara ^a   Di Pietro, Alessandra ^a   Ferrucci, Pier Francesco ^a  

^a EUROPEAN INSTITUTE OF ONCOLOGY   (Italy)

Author keywords

electrochemotherapy; melanoma; primary skin tumors; skin metastases; subcutaneous lesions

Indexed keywords

BLEOMYCIN; CISPLATIN;

ANESTHESIA; BASAL CELL CARCINOMA; BREAST ADENOCARCINOMA; BREAST CANCER; CLINICAL PRACTICE; DRUG EFFICACY; DRUG SAFETY; ELECTRIC CURRENT; ELECTROCHEMOTHERAPY; ELECTROPORATION; HEAD AND NECK CARCINOMA; HUMAN; KAPOSI SARCOMA; MELANOMA; PATIENT MONITORING; PATIENT SELECTION; PULSE GENERATOR; REVIEW; SKIN TUMOR; SQUAMOUS CELL CARCINOMA; TREATMENT RESPONSE; TUMOR VOLUME;

ANIMALS; ANTINEOPLASTIC AGENTS; BLEOMYCIN; CISPLATIN; ELECTROCHEMOTHERAPY; HUMANS; SKIN; SKIN NEOPLASMS; TREATMENT OUTCOME;

EID: 78449312393     PISSN: 13960296     EISSN: 15298019     Source Type: Journal    
DOI: 10.1111/j.1529-8019.2010.01370.x     Document Type: Review

References (51)

1. Neumann E, Schaefer-Ridder M, Wang Y, Hofschneider PH,. Gene transfer into mouse lyoma cells by electroporation in high electric fields. EMBO J 1982: 1: 841-845.
2. Gehl J,. Electroporation: theory and methods, perspectives for drug delivery, gene therapy and research. Acta Physiol Scand 2003: 177: 437-447.
3. Moller MG, Salwa S, Soden DM, O'Sullivan GC,. Electrochemotherapy as an adjunct or alternative to other treatments for unresectable or in-transit melanoma. Expert Rev Anticancer Ther 2009: 9: 1611-1630.
4. Sadadcharam M, Soden DM, O'Sullivan GC,. Electrochemotherapy: an emerging cancer treatment. Int J Hyperthermia 2008: 24: 263-273.
5. Mir L,. Bases and rationale of the electrochemotherapy. Eur J Cancer Suppl 2006: 4: 38-44.
6. Gimbel MI, Delman KA, Zager JS,. Therapy for unresectable recurrent and in-transit extremity melanoma. Cancer Control 2008: 15: 225-232.
7. Orlowski S, Belehradek J Jr, Paoletti C, Mir LM,. Transient electropermeabilization of cells in culture. Increase of the cytotoxicity of anticancer drugs. Biochem Pharmacol 1988: 37: 4727-4733.
8. Larkin JO, Collins CG, Aarons S, et al. Electrochemotherapy: aspects of preclinical development and early clinical experience. Ann Surg 2007: 245: 469-479.
9. Gehl J,. Electroporation for drug and gene delivery in the clinic: doctors go electric. Methods Mol Biol 2008: 423: 351-359.
10. Mir LM, Banoun H, Paoletti C,. Introduction of definite amounts of nonpermeant molecules into living cells after electropermeabilization: direct access to the cytosol. Exp Cell Res 1988: 175: 15-25.
11. Melvik JE, Pettersen EO, Gordon PB, Seglen PO,. Increase in cis-dichlorodiammineplatinum (II) cytotoxicity upon reversible electropermeabilization of the plasma membrane in cultured human NHIK 3025 cells. Eur J Cancer Clin Oncol 1986: 22: 1523-1530.
12. Okino M, Mohri H,. Effects of a high-voltage electrical impulse and an anticancer drug on in vivo growing tumors. Jpn J Cancer Res 1987: 78: 1319-1321.
13. Mir LM, Belehradek M, Domenge C, et al. Electrochemotherapy, a new antitumor treatment: first clinical trial. C R Acad Sci III 1991: 313: 613-618.
14. Belehradek M, Domenge C, Luboinski B, Orlowski S, Belehradek J Jr, Mir LM,. Electrochemotherapy, a new antitumor treatment. First clinical phase I-II trial. Cancer 1993: 72: 3694-3700.
15. Gothelf A, Mir LM, Gehl J,. Electrochemotherapy: results of cancer treatment using enhanced delivery of bleomycin by electroporation. Cancer Treat Rev 2003: 29: 371-387.
16. Sersa G, Cemazar M, Rudolf Z,. Electrochemotherapy: advantages and drawbacks in treatment of cancer patients. Cancer Ther 2003: 1: 133-142.
17. Rudolf Z, Stabuc B, Cemazr M, et al. Electrochemotherapy with bleomycin. The first clinical experience in malignant melanoma patients. Radiol Oncol 1995: 29: 229-235.
18. Glass LF, Pepine ML, Fenske NA, Jaroszeski M, Reintgen DS, Heller R,. Bleomycin-mediated electrochemotherapy of metastatic melanoma. Arch Dermatol 1996: 132: 1353-1357.
19. Heller R, Jaroszeski MJ, Reintgen DS, et al. Treatment of cutaneous and subcutaneous tumors with electrochemotherapy using intralesional bleomycin. Cancer 1998: 83: 148-157. (Pubitemid 28299641)
20. Mir LM, Glass LF, Sersa G, et al. Effective treatment of cutaneous and subcutaneous malignant tumours by electrochemotherapy. Br J Cancer 1998: 77: 2336-2342.
21. Sersa G, Stabuc B, Cemazar M, Jancar B, Miklavcic D, Rudolf Z,. Electrochemotherapy with cisplatin: potentiation of local cisplatin antitumour effectiveness by application of electric pulses in cancer patients. Eur J Cancer 1998: 34: 1213-1218.
22. Sersa G, Stabuc B, Cemazar M, Miklavcic D, Rudolf Z,. Electrochemotherapy with cisplatin: clinical experience in malignant melanoma patients. Clin Cancer Res 2000: 6: 863-867.
23. Snoj M, Rudolf Z, Cemazar M, Jancar B, Sersa G,. Successful sphincter-saving treatment of anorectal malignant melanoma with electrochemotherapy, local excision and adjuvant brachytherapy. Anticancer Drugs 2005: 16: 345-348.
24. Marty MSG, Garbay JR, Gehl J, et al. Electrochemotherapy - an easy, highly effective and safe treatment of cutaneous and subcutaneous metastases: results of ESOPE (European Standard Operating Procedures of Electrochemotherapy) study. Eur J Cancer Suppl 2006: 4: 3-13.
25. Campana LG, Mocellin S, Basso M, et al. Bleomycin-based electrochemotherapy: clinical outcome from a single institution's experience with 52 patients. Ann Surg Oncol 2009: 16: 191-199.
26. Quaglino P, Mortera C, Osella-Abate S, et al. Electrochemotherapy with intravenous bleomycin in the local treatment of skin melanoma metastases. Ann Surg Oncol 2008: 15: 2215-2222.
27. Heller R, Jaroszeski MJ, Glass LF, et al. Phase I/II trial for the treatment of cutaneous and subcutaneous tumors using electrochemotherapy. Cancer 1996: 77: 964-971.
28. Domenge C, Orlowski S, Luboinski B, et al. Antitumor electrochemotherapy: new advances in the clinical protocol. Cancer 1996: 77: 956-963.
29. Glass LF, Fenske NA, Jaroszeski M, et al. Bleomycin-mediated electrochemotherapy of basal cell carcinoma. J Am Acad Dermatol 1996: 34: 82-86.
30. Glass LF, Jaroszeski M, Gilbert R, Reintgen DS, Heller R,. Intralesional bleomycin-mediated electrochemotherapy in 20 patients with basal cell carcinoma. J Am Acad Dermatol 1997: 37: 596-599.
31. Kubota Y, Mir LM, Nakada T, Sasagawa I, Suzuki H, Aoyama N,. Successful treatment of metastatic skin lesions with electrochemotherapy. J Urol 1998: 160: 1426.
32. Panje WR, Hier MP, Garman GR, Harrell E, Goldman A, Bloch I,. Electroporation therapy of head and neck cancer. Ann Otol Rhinol Laryngol 1998: 107: 779-785.
33. Rols MP, Bachaud JM, Giraud P, Chevreau C, Roche H, Teissie J,. Electrochemotherapy of cutaneous metastases in malignant melanoma. Melanoma Res 2000: 10: 468-474.
34. Gehl J, Geertsen PF,. Efficient palliation of haemorrhaging malignant melanoma skin metastases by electrochemotherapy. Melanoma Res 2000: 10: 585-589.
35. Sersa G, Cufer T, Cemazar M, Rebersek M, Zvonimir R,. Electrochemotherapy with bleomycin in the treatment of hypernephroma metastasis: case report and literature review. Tumori 2000: 86: 163-165.
36. Sersa G, Stabuc B, Cemazar M, Miklavcic D, Rudolf Z,. Electrochemotherapy with cisplatin: the systemic antitumour effectiveness of cisplatin can be potentiated locally by the application of electric pulses in the treatment of malignant melanoma skin metastases. Melanoma Res 2000: 10: 381-385.
37. Rodriguez-Cuevas S, Barroso-Bravo S, Almanza-Estrada J, Cristobal-Martinez L, Gonzalez-Rodriguez E,. Electrochemotherapy in primary and metastatic skin tumors: phase II trial using intralesional bleomycin. Arch Med Res 2001: 32: 273-276.
38. Allegretti JP, Panje WR,. Electroporation therapy for head and neck cancer including carotid artery involvement. Laryngoscope 2001: 111: 52-56.
39. Shimizu T, Nikaido T, Gomyo H, et al. Electrochemotherapy for digital chondrosarcoma. J Orthop Sci 2003: 8: 248-251.
40. Burian M, Formanek M, Regele H,. Electroporation therapy in head and neck cancer. Acta Otolaryngol 2003: 123: 264-268.
41. Rebersek M, Cufer T, Cemazar M, Kranjc S, Sersa G,. Electrochemotherapy with cisplatin of cutaneous tumor lesions in breast cancer. Anticancer Drugs 2004: 15: 593-597.
42. Bloom DC, Goldfarb PM,. The role of intratumour therapy with electroporation and bleomycin in the management of advanced squamous cell carcinoma of the head and neck. Eur J Surg Oncol 2005: 31: 1029-1035.
43. Byrne CM, Thompson JF, Johnston H, et al. Treatment of metastatic melanoma using electroporation therapy withbleomycin (electrochemotherapy). Melanoma Res 2005: 15: 45-51.
44. Mir L, Gehl J, Sersa G, et al. Standard operating procedures of the electrochemotherapy: instructions for the use of bleomycin or cisplatin administered either systemically or locally and electric pulses delivered by the CliniporatorTM by means of invasive or non-invasive electrodes. Eur J Cancer Suppl 2006: 4: 14-25.
45. Sersa G,. The state-of-the-art of electrochemotherapy before the ESOPE study; advantages and clinical uses. Eur J Cancer Suppl 2006: 4: 52-59.
46. Gaudy C, Richard MA, Folchetti G, Bonerandi JJ, Grob JJ,. Randomized controlled study of electrochemotherapy in the local treatment of skin metastases of melanoma. J Cutan Med Surg 2006: 10: 115-121.
47. Byrne CM, Thompson JF,. Role of electrochemotherapy in the treatment of metastatic melanoma and other metastatic and primary skin tumors. Expert Rev Anticancer Ther 2006: 6: 671-678.
48. Soden DM, Larkin JO, Collins CG, et al. Successful application of targeted electrochemotherapy using novel flexible electrodes and low dose bleomycin to solid tumours. Cancer Lett 2006: 232: 300-310.
49. Soden D, Larkin J, Collins C, et al. The development of novel flexible electrode arrays for the electrochemotherapy of solid tumour tissue. (Potential for endoscopic treatment of inaccessible cancers). Conf Proc IEEE Eng Med Biol Soc 2004: 5: 3547-3550.
50. Andersen MH, Gehl J, Reker S, et al. Dynamic changes of specific T cell responses to melanoma correlate with IL-2 administration. Semin Cancer Biol 2003: 13: 449-459.
51. Roux S, Bernat C, Al-Sakere B, et al. Tumor destruction using electrochemotherapy followed by CpG oligodeoxynucleotide injection induces distant tumor responses. Cancer Immunol Immunother 2008: 57: 1291-1300.